Rexahn Pharmaceuticals (Rexahn) has reported top-line results from a phase IIa clinical study of Serdaxin, its major depressive disorder (MDD) drug candidate. Reportedly, the randomised, double blind, placebo
Celsion Corporation (Celsion) has received approval from the regulatory agencis in the Philippines and Malaysia for its pivotal phase III primary liver cancer clinical trial application. Reportedly, Celsion’s
“For over 30 years, Thermo Fisher has thrived as a major employer in Frederick County,” Governor Kaine said. “By investing and expanding in the Commonwealth, Thermo Fisher will
The FDA has issued a Complete Response Letter to Amgen for its Biologic License Applications (BLA) for Prolia (denosumab) in the treatment and prevention of postmenopausal osteoporosis. Reportedly,
The FDA has approved GlaxoSmithKline’s (GSK) Votrient (pazopanib) to treat patients with advanced renal cell carcinoma (RCC). Votrient, a once-daily, oral medication, is an angiogenesis inhibitor which may
Bio-Bridge Science has received a business license from the Beijing Administration for Industry and Commerce of the People’s Republic of China (PRC) indicating approval of the formation of
Sanofi-Aventis has launched ClikSTAR in Canada. The Health Canada has approved the ClikSTAR reusable insulin pen for use with Lantus, giving patients with diabetes an additional option to
MWV has received chain-of-custody certifications to the Forest Stewardship Council (FSC) and the Programme for the Endorsement of Forest Certification scheme (PEFC) for two of its packaging manufacturing
Allion Healthcare has entered into a definitive merger agreement with HIG Capital. As per the agreement, Allion will be acquired and taken private by an affiliate of HIG
Angiochem’s ANG1005 has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate phase 1 /2 clinical studies in patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.